ARA

Telehealth Prescribing of Schedule II Substances in New Jersey

A Policy Analysis of New Jersey P.L.2026, c.40 (A4852), Its Relationship to Federal DEA Telemedicine Rules, and the Evidence on Remote Prescribing of Stimulants and Opioids

Shruthi Nandakumar

References

SCHOLARLY, DATA, AND PRESS SOURCES

American Academy of Child and Adolescent Psychiatry. 2025. "Special Registration for Telemedicine and Limited State Telemedicine Registrations, Docket No. DEA-407, RIN 1117-AB40." Comment letter to Derek S. Maltz, Acting Administrator, U.S. Drug Enforcement Administration, March 18. https://www.aacap.org/App_Themes/AACAP/Docs/Advocacy/regulatory_issues/2025/DEA_Comments_Special_Registration.pdf (accessed September 29, 2026).

American Medical Association. 2025. "March 21, 2025: National Advocacy Update." March 21. https://www.ama-assn.org/health-care-advocacy/advocacy-update/march-21-2025-national-advocacy-update (accessed September 29, 2026).

American Psychiatric Association. 2025. "Special Registration for Telemedicine and Limited State Telemedicine Registrations Proposed Rule (Docket No. DEA-407)." Comment letter to Derek Maltz, Acting Administrator, U.S. Drug Enforcement Administration, March 18. https://www.psychiatry.org/getattachment/d7c12b06-96cf-4062-b16a-9eb262d1ff6f/APA-Letter-DEA-Special-Registration-03182025.pdf (accessed September 29, 2026).

ATA Action. 2025. "ATA Action Calls for Meaningful Changes to DEA's Special Registration for Telemedicine and Limited State Telemedicine Registrations Proposed Rule." Press release, February 18. https://www.americantelemed.org/press-releases/ata-action-calls-for-meaningful-changes-to-deas-special-registration-for-telemedicine-and-limited-state-telemedicine-registrations-proposed-rule/ (accessed September 29, 2026).

Center for Connected Health Policy. 2026. "State Telehealth Policies: Online Prescribing." https://www.cchpca.org/topic/online-prescribing/ (accessed September 29, 2026, and October 21, 2026).

Creedon, Timothy B., Hefei Wen, Mir M. Ali, and Rebecca L. Haffajee. 2025. "Trends in Telehealth Initiation of Prescription Stimulants for Child and Adult Enrollees in Medicaid and CHIP During COVID-19." *Health Affairs* 44 (8): 996–1004. https://doi.org/10.1377/hlthaff.2024.01659.

Hammerslag, Lindsey R., Aimee Mack, Redonna K. Chandler, Laura C. Fanucchi, Daniel J. Feaster, Marc R. LaRochelle, Michelle R. Lofwall, Michael Nau, Jennifer Villani, Sharon L. Walsh, Philip M.

Westgate, Svetla Slavova, and Jeffery C. Talbert. 2023. “Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.” *JAMA Network Open* 6 (10): e2336914. https://doi.org/10.1001/jamanetworkopen.2023.36914.

Huskamp, Haiden A., Lori Uscher-Pines, Pushpa Raja, Sharon-Lise T. Normand, Ateev Mehrotra, and Alisa B. Busch. 2024. “Trends in Use of Telemedicine for Stimulant Initiation Among Children and Adults.” *Psychiatric Services* 75 (7): 630–37. https://doi.org/10.1176/appi.ps.20230421.

Jones, Christopher M., Carla Shoff, Kevin Hodges, Carlos Blanco, Jan L. Losby, Shari M. Ling, and Wilson M. Compton. 2022. “Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.” *JAMA Psychiatry* 79 (10): 981–92. https://doi.org/10.1001/jamapsychiatry.2022.2284.

Jones, Christopher M., Carla Shoff, Carlos Blanco, Jan L. Losby, Shari M. Ling, and Wilson M. Compton. 2023. “Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.” *JAMA Psychiatry* 80 (5): 508–14. https://doi.org/10.1001/jamapsychiatry.2023.0310.

Monico, Laura B., Elizabeth A. Bambury, Jennifer K. Foreman, Melody Avila, and Stephen A. Martin. 2026. “Retention in Telehealth-Delivered Buprenorphine Treatment for Opioid Use Disorder: Multistate Retrospective Cohort Study.” *Journal of Medical Internet Research* 28: e100527. https://doi.org/10.2196/100527.

Myran, Daniel T., Rachael MacDonald-Spracklin, Giovanna Busa, Robert Talarico, and Yaron Finkelstein. 2025. “Population-Level Trends in Attention-Deficit/Hyperactivity Disorder Medication Prescribing.” *JAMA Network Open* 8 (12): e2548532. https://doi.org/10.1001/jamanetworkopen.2025.48532.

Nagappan, Ashwini, Austin Miller, Sanjula Jain, and Allison H. Oakes. 2024. “Stimulant, Antidepressant, and Opioid Telehealth Prescription Trends Between 2019 and 2022.” *JAMA Network Open* 7 (9): e2433334. https://doi.org/10.1001/jamanetworkopen.2024.33334.

National Association of State Controlled Substances Authorities. 2026. “DEA Gets Closer to Finalizing Telemedicine Special Registration.” September 18. https://nascsa.org/dea-gets-closer-to-finalizing-telemedicine-special-registration/ (accessed September 29, 2026).

New Jersey Assembly Democrats. 2026. “LD11 Sponsored Legislation Eases Prescription of Schedule II Medications By Telemedicine.” Press release, July 15. https://www.assemblydems.com/CivicAlerts.asp?AID=13146 (accessed October 21, 2026).

New Jersey Division of Consumer Affairs, Drug Control Unit. 2026a. Updated alert on Schedule II CDS prescribing through telemedicine following expiration of the COVID-19 waivers, modifying the Division’s communication of February 13, 2026. Issued between February 20 and March 9, 2026. Original not obtained; described in Simone et al. (2026a).

New Jersey Division of Consumer Affairs, Drug Control Unit. 2026b. “Notice Regarding Schedule II CDS Telemedicine Prescriptions.” August 3. https://www.njconsumeraffairs.gov/dcu (accessed September 29, 2026).

New Jersey Office of the Chief State Medical Examiner. n.d. “New Jersey Medical Aid in Dying for the Terminally Ill Act, 2024 Data Summary.” https://deathwithdignity.org/wp-content/uploads/2025/08/NJ-2024.pdf (accessed October 21, 2026).

Office of Information and Regulatory Affairs. 2026. “Special Registrations for Telemedicine and Limited State Telemedicine Registrations.” EO 12866 regulatory review record, RIN 1117-AB40, received August 25. https://www.reginfo.gov/public/do/eoDetails?rrid=1510512 (accessed October 27, 2026).

Office of the Governor of New Jersey. 2026. “Governor Sherrill Signs Legislation.” Press release, July 8. https://www.nj.gov/governor/news/2026/approved/20260708a.shtml (accessed September 29, 2026).

Rao, Vinod, Sylvia Lanni, Amy M. Yule, Sean E. McCabe, Philip T. Veliz, Ty S. Schepis, and Timothy E. Wilens. 2025. “Telehealth Prescribing of Stimulants for ADHD and Associated Risk for Later Stimulant and Substance Use Disorders.” *American Journal of Psychiatry* 182 (8): 779–88. https://doi.org/10.1176/appi.ajp.20240346.

Roman, Jackie. 2026. “ADHD Patients in N.J. Can Now Refill Their Medications From Home.” *NJ.com*, July 10. https://www.nj.com/healthfit/2026/07/adhd-patients-in-nj-can-now-refill-their-medications-from-home.html (accessed September 29, 2026).

Sherrill, Mikie (@GovSherrillNJ). 2026. “This week, I signed legislation that makes permanent certain telehealth prescription flexibilities by eliminating the need for in-person visits every three months.” Post on X, July 9. https://x.com/GovSherrillNJ/status/2075278817195700270 (accessed October 21, 2026).

Simone, Rebecca, Jéna M. Grady, Michele A. Masucci, Mambwe Mutanuka-Hiebel, and Sravya Rallapalli. 2026a. "New Jersey Issues Modified Guidance on Schedule II CDS Prescribing Requirements." Client alert, Nixon Peabody LLP, March 9. https://www.nixonpeabody.com/insights/alerts/2026/03/09/new-jersey-issues-modified-guidance-on-prescribing-requirements (accessed October 21, 2026).

Simone, Rebecca, Jéna M. Grady, Michele A. Masucci, Mambwe Mutanuka-Hiebel, and Sravya Rallapalli. 2026b. "New Jersey Expands Telemedicine Rules for Schedule II Controlled Drug Substances." Client alert, Nixon Peabody LLP, July 16. https://www.nixonpeabody.com/insights/alerts/2026/07/16/nj-expands-telemedicine-rules-for-schedule-ii-controlled-drug-substances (accessed September 29, 2026).

Sousa, Jessica L., Rachel K. Landis, Ben Senator, Shona Olalere, Jessica Rigsby, Lexie Minarik, Phoebe Levine, Desiree' Anderson, Arthur Robin Williams, and Laura J. Faherty. 2026. "State Tele-Buprenorphine Prescribing Policies by Medical Professional Type." *JAMA Health Forum* 7 (4): e260420. https://doi.org/10.1001/jamahealthforum.2026.0420.

Stein, Bradley D., Brendan K. Saloner, Flora Sheng, Mark Sorbero, Andrew W. Dick, and Adam J. Gordon. 2025. "Associations Between State Policies Facilitating Telehealth and Buprenorphine Episode Initiation and Duration Early in the COVID Pandemic." *Journal of General Internal Medicine* 40 (9): 1986–94. https://doi.org/10.1007/s11606-024-09188-6.

U.S. Drug Enforcement Administration. 2025. "DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care." Press release, December 31. https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care (accessed September 29, 2026).

U.S. Drug Enforcement Administration and U.S. Food and Drug Administration. 2023. "DEA and FDA Issue Joint Letter to the Public." August 1. https://www.dea.gov/sites/default/files/2023-08/DEA%20and%20FDA%20Issue%20Joint%20Letter%20to%20the%20Public.pdf (accessed September 29, 2026).

LEGAL AUTHORITIES

Cases

Gonzales v. Oregon, 546 U.S. 243 (2006).

Federal Statutes and Public Laws

21 U.S.C. § 829(e).

Ryan Haight Online Pharmacy Consumer Protection Act of 2008, Pub. L. No. 110-425, 122 Stat. 4820 (codified as amended in scattered sections of 21 U.S.C.), https://www.govinfo.gov/content/pkg/PLAW-110publ425/pdf/PLAW-110publ425.pdf.

Federal Regulations and Federal Register Documents

21 C.F.R. § 1306.04 (2025).

21 C.F.R. § 1306.07 (2025).

Continuity of Care via Telemedicine for Veterans Affairs Patients, 90 Fed. Reg. 6523 (Jan. 17, 2025) (codified at 21 C.F.R. pt. 1306), https://www.govinfo.gov/content/pkg/FR-2025-01-17/pdf/2025-01044.pdf.

Expansion of Buprenorphine Treatment via Telemedicine Encounter, 90 Fed. Reg. 6504 (Jan. 17, 2025) (codified at 21 C.F.R. pt. 1306), https://www.govinfo.gov/content/pkg/FR-2025-01-17/pdf/2025-01049.pdf.

Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 90 Fed. Reg. 13410 (Mar. 24, 2025) (delaying effective date to Dec. 31, 2025), https://www.govinfo.gov/content/pkg/FR-2025-03-24/pdf/2025-05007.pdf.

Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, 90 Fed. Reg. 61301 (Dec. 31, 2025) (codified at 21 C.F.R. pt. 1307 and 42 C.F.R. pt. 12), https://www.govinfo.gov/content/pkg/FR-2025-12-31/pdf/2025-24123.pdf.

Medications for the Treatment of Opioid Use Disorder, 89 Fed. Reg. 7528 (Feb. 2, 2024) (codified at 42 C.F.R. pt. 8), https://www.govinfo.gov/content/pkg/FR-2024-02-02/pdf/2024-01693.pdf.

Special Registrations for Telemedicine and Limited State Telemedicine Registrations, 90 Fed. Reg. 6541 (proposed Jan. 17, 2025) (to be codified at 21 C.F.R. pts. 1300, 1301, 1304, 1306), https://www.govinfo.gov/content/pkg/FR-2025-01-17/pdf/2025-01099.pdf.

New Jersey Statutes, Session Laws, and Regulations

N.J. Stat. Ann. §§ 45:1-44 to -50.2 (West 2026) (Prescription Monitoring Program), https://www.njconsumeraffairs.gov/Statutes/NJ-Prescription-Monitoring-Program-Law.pdf.

P.L.2017, c.117 (N.J.) (codified as amended at N.J. Stat. Ann. §§ 45:1-61 to -66 and in scattered sections of N.J. Stat. Ann.), https://pub.njleg.gov/bills/2016/AL17/117_.HTM.

P.L.2019, c.59 (N.J.) (Medical Aid in Dying for the Terminally Ill Act) (codified at N.J. Stat. Ann. § 26:16-1 et seq.), https://pub.njleg.gov/Bills/2018/PL19/59_.HTM.

P.L.2026, c.29 (N.J.) (approved June 30, 2026) (amending P.L.2021, c.310, § 11), https://pub.njleg.state.nj.us/Bills/2026/AL26/29_.PDF.

P.L.2026, c.40 (N.J.) (approved July 8, 2026) (amending N.J. Stat. Ann. § 45:1-62), https://pub.njleg.state.nj.us/Bills/2026/AL26/40_.PDF.

Bills

Assemb. B. 4852, 222d Leg., 1st Ann. Sess. (N.J. 2026) (as introduced May 4, 2026), https://pub.njleg.state.nj.us/Bills/2026/A5000/4852_I1.PDF.

Assemb. Comm. Substitute for Assemb. B. 4852, 222d Leg., 1st Ann. Sess. (N.J. 2026) (adopted June 23, 2026), https://pub.njleg.state.nj.us/Bills/2026/A5000/4852_U1.HTM.

N.J. Legislature, Bill Detail: A4852 (2026–2027 Sess.), https://www.njleg.state.nj.us/bill-search/2026/A4852 (last visited Sept. 29, 2026).

S.B. 4194, 222d Leg., 1st Ann. Sess. (N.J. 2026) (as introduced May 11, 2026), https://pub.njleg.gov/Bills/2026/S4500/4194_I1.HTM.

S.B. 4210, 222d Leg., 1st Ann. Sess. (N.J. 2026) (as introduced May 11, 2026), https://pub.njleg.gov/Bills/2026/S4500/4210_I1.HTM.

S. Comm. Substitute for S.B. 4194 & 4210, 222d Leg., 1st Ann. Sess. (N.J. 2026) (reported June 11, 2026), https://pub.njleg.gov/Bills/2026/S4500/4194_U1.PDF.

Legislative Statements

Assemb. State & Loc. Gov't Comm., Statement to Assemb. Comm. Substitute for Assemb. B. 4852, 222d Leg., 1st Ann. Sess. (N.J. June 23, 2026), https://pub.njleg.state.nj.us/Bills/2026/A5000/4852_S1.HTM.

S. Health, Hum. Servs. & Senior Citizens Comm., Statement to S. Comm. Substitute for S.B. 4194 & 4210, 222d Leg., 1st Ann. Sess. (N.J. June 11, 2026), https://pub.njleg.state.nj.us/Bills/2026/S4500/4194_S1.HTM.

Executive and Administrative Orders

N.J. Div. of Consumer Affs., Admin. Order No. 2020-15 & Waiver No. W-2020-14 (Aug. 11, 2020) (expired Feb. 16, 2026), https://www.njconsumeraffairs.gov/COVID19/Documents/DCA-AO-2020-15_DCA-W-2020-14.pdf.

N.J. Exec. Order No. 13 (Feb. 13, 2026) (extending the State of Emergency declared in Exec. Order No. 103 (2020) for limited purposes to Apr. 2, 2026), https://nj.gov/infobank/eo/057sherrill/pdf/EO-13.pdf.

N.J. Exec. Order No. 415 (Jan. 16, 2026), https://nj.gov/infobank/eo/056murphy/pdf/EO-415.pdf.

Enforcement Records

Non-Prosecution Agreement Between the U.S. Att'y's Off. for the E. Dist. of N.Y. and Cerebral, Inc. (Nov. 1, 2024), https://www.justice.gov/usao-edny/media/1376051/dl?inline.

Press Release, U.S. Dep't of Just., Off. of Pub. Affs., Founder/CEO and Clinical President of Digital Health Company Convicted in $100M Adderall Distribution and Health Care Fraud Scheme (Nov. 19, 2025), https://www.justice.gov/opa/pr/founderceo-and-clinical-president-digital-health-company-convicted-100m-adderall.

Press Release, U.S. Dep't of Just., Off. of Pub. Affs., Founder/CEO and Clinical President of Digital Health Company Sentenced to 72 Months and 24 Months, Respectively, for $90 Million Scheme to Distribute over 37 Million Pills of Adderall (July 7, 2026), https://www.justice.gov/opa/pr/founderceo-and-clinical-president-digital-health-company-sentenced-8-years-90-million-scheme.

Document control. Version 1.0, October 2026. Author: Shruthi Nandakumar, Director of Research and Programs.

Contact: https://www.agardresearchassociates.org/contact-us

Telehealth Prescribing of Schedule II Substances in New Jersey: A Policy Analysis of New Jersey P.L.2026, c.40 (A4852), Its Relationship to Federal DEA Telemedicine Rules, and the Evidence on Remote Prescribing of Stimulants and Opioids © 2026 by Agard Research Associates Inc. is licensed under CC BY-NC-ND 4.0.

To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-nd/4.0/